Clinical Trial: Selinexor in Initial or Relapsed/Refractory Richter's Transformation
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Initial or Refractory and/or Relapsed Overall Response Rate (ORR) (as defined by the IWG Criteria)
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Karyopharm Therapeutics Inc
Dates:
Date Received: May 13, 2014
Date Started: November 2014
Date Completion:
Last Updated: April 4, 2017
Last Verified: April 2017